Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury

Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury
Neuren Pharmaceuticals chief executive Jon Pilcher says the Kiwi firm is in a privileged position. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
Neuren Pharmaceuticals' boss Jon Pilcher says he was punching the air after leaving a recent successful meeting with the US Food and Drug Administration.Neuren, a local company which develops treatments for neurological disorders including Rett syndrome, has been cleared to begin phase-three trials for the drug NNZ-2591 to treat Phelan-McDermid syndrome. It will be the first-ever phase-three trial in children with the rare genetic condition.The disorders Neuren targets for treatment with its drugs are often debilitating and can ha...

More Markets

Kids KiwiSaver mooted to invest in children's future
Finance

Kids KiwiSaver mooted to invest in children's future

Proposed savings programme could accumulate up to $18 billion in 18 years.

Why Bremworth had to ditch its wool-only strategy
Primary Sector

Why Bremworth had to ditch its wool-only strategy

Carpet maker had private talks about the Godfrey Hirst deal after its AGM.

Mainfreight result lifts market as investors eye Infratil update
Markets

Mainfreight result lifts market as investors eye Infratil update

Positive news from the logistics and transport company has buoyed the NZX.

Tom Raynel 12 Nov 2025
Account-checking technology poised for wider rollout
Finance

Account-checking technology poised for wider rollout

Confirmation of Payee technology used in 60 million-plus transactions in first year.

Andy Macdonald 12 Nov 2025